1.Diagnostic value of PIV,APRI,and FIB-4 in intrahepatic cholestasis of pregnancy
China Modern Doctor 2025;63(26):33-36
Objective To investigate the diagnostic value of pan-immune-inflammation value(PIV),aspartate aminotransferase to platelet ratio index(APRI)and fibrosis-4 index(FIB-4)in intrahepatic cholestasis of pregnancy(ICP).Methods A total of 312 pregnant women who underwent prenatal care and childbirth at Anhui Women and Children's Medical Center from September 2022 to December 2024 were selected as subjects.Among them,156 patients diagnosed with ICP were included in ICP group,while 156 healthy pregnant women formed control group.The study compared differences in PIV,APRI,and FIB-4 levels between two groups.Receiver operating characteristic(ROC)curves were used to evaluate the predictive capabilities of PIV,APRI,and FIB-4 indicators for ICP occurrence,both individually and in combination.Results Inflammatory response is involved in the occurrence of ICP,and PIV,APRI,and FIB-4 have good diagnostic value for ICP.When PIV and APRI are combined,they have higher diagnostic value in ICP group showed significantly higher PIV,APRI,and FIB-4 levels compared to control group(P<0.05).The area under the curve(AUC)for diagnosing ICP using PIV,APRI,and FIB-4 were 0.636,0.751,and 0.627,respectively.When PIV combined with APRI,the diagnostic AUC reached 0.829 with sensitivity of 73.1%and specificity of 83.3%.Conclusion Inflammatory response is involved in the occurrence of ICP,and PIV,APRI and FIB-4 have good diagnostic value for ICP.Combination of PIV and APRI shows excellent diagnostic value.
2.Application of ArcherQA for independent dose verification of SRT plans for CyberKnife
Xuyao YU ; Yuwen WANG ; Yang DONG ; Daguang ZHANG ; Yongchun SONG ; Qiang REN ; Xi PEI ; Zhiyong YUAN ; Wei WANG ; Jianrong DAI
Chinese Journal of Radiation Oncology 2025;34(11):1139-1145
Objective:To evaluate the feasibility of using the domestic ArcherQA system for fast and simplified independent verification of CyberKnife (CK) stereotactic radiotherapy (SRT) plans.Methods:SRT plans of 57 patients treated with CK at Tianjin Medical University Cancer Institute and Hospital from August 2021 to August 2022 were retrospectively analyzed, including 15 intracranial, 30 pulmonary, and 12 abdominal tumors cases. Point-dose and planar-dose verifications were performed using an ionization chamber and radiochromic films embedded in a homogeneous phantom, and the results were compared with those calculated by the treatment planning system (TPS). The localization CT images and corresponding SRT plans were imported into the ArcherQA system for independent dose verification and analysis. The correlation between ArcherQA results and phantom measurements was analyzed, with comparisons of target mean dose differences and γ pass rates.Results:Phantom measurement results showed, the measured point-dose differences for intracranial, lung, and abdominal plans were -0.94% ± 3.22%, 1.92% ± 2.05%, and 2.12% ± 0.77%, respectively. The mean dose differences in target dose calculation between ArcherQA and TPS: intracranial in the gross tumor volume (GTV) regions were 0.34% ± 2.21%, lung tumor GTV were -2.47% ± 2.46%, and abdominal tumor GTV were 0.80% ± 2.61%, respectively. Among them, the abdominal GTV region showed the highest correlation between ArcherQA and measured results ( r=0.78). The average two-dimensional γ pass rates (2 mm/2%, threshold=10%) measured using phantom films were 95.92% ± 2.35% for intracranial, 95.70% ± 2.74% for lung, and 96.74% ± 3.41% for abdominal tumors plans, respectively. The three-dimensional ArcherQA results showed comparable γ pass rates (1 mm/2%, threshold=10%) for lung and abdominal GTV and PTV regions, with similar medians and data dispersion to film measurements. Conclusions:The ArcherQA system enables rapid and efficient independent dose verification of CK SRT plans without the need for additional hardware. The verification results show good correlation with phantom measurements, supporting its potential as an auxiliary quality assurance tool in clinical CK SRT implementation.
3.Current situation analysis and quality evaluation of guidelines and consensus in ovarian stimulation for in vitro fertilization
Yuan GAO ; Zaiwei SONG ; Dan JIANG ; Rui YANG ; Yuwen HUANG ; Rong LI ; Rongsheng ZHAO
Chinese Journal of Reproduction and Contraception 2025;45(8):818-825
Objective:To systematically evaluate the current status and methodological quality of guideline and consensus in ovarian stimulation for in vitro fertilization (IVF), and to provide reference for the development of future guidelines and research. Methods:A systematic search was conducted in databases including PubMed, Embase, CNKI, Wanfang, Sinomed and relevant guideline websites from inceptions to October 2024. Data were extracted from the literature that met the inclusion criteria, and methodological quality was assessed using the Appraisal of Guidelines for Research and Evaluation Ⅱ (AGREE Ⅱ) tool. Descriptive analysis was performed with results presented in visual data charts.Results:A total of 23 studies were included, with 8 guidelines and 15 consensus. Totally 21 (91.3%) studies focused on the selection of ovarian stimulation protocols, with the majority concentrating on protocols for patients undergoing IVF treatment for the first cycle, and 12 (52.2%) studies focused on the selection of gonadotropin starting dosage. In terms of methodology, the average standardized scores in the 6 assessment domains of the AGREE Ⅱ tool were as follows: scope and purpose (85.1%), stakeholder involvement (66.6%), rigour of development (36.5%), clarity of presentation (70.1%), applicability (36.4%), and editorial independence (46.2%).Conclusion:Current recommendations in ovarian stimulation for IVF exhibit inconsistencies, and the methodological quality varies, which partially hinders the translation of evidence into clinical practice. Future research should further focus on the selection of ovarian stimulation protocols and gonadotropin starting dosage, promoting the update and refinement of guidelines and consensus to guide the precise treatment of ovarian stimulation.
4.Visual Analysis of Current Situation,Hotspot and Trend of Traditional Chinese Medicine in Treating Carotid Atherosclerosis Based on CiteSpace and VOSviewer
Yihuan CHEN ; Di ZHANG ; Yuwen XIA ; Junjie JIANG ; Cheng LYU ; Qingqiao SONG ; Yong TAN
World Science and Technology-Modernization of Traditional Chinese Medicine 2025;27(2):498-507
Objective To explore the current situation,hot spots and trends of clinical research on the treatment of carotid atherosclerosis(CAS)with traditional Chinese medicine.Methods Search CNKI,Wanfang,VIP,Web of Science core collection database related literature,using Python 3.9.6 cleaning data,using CiteSpace and VOSviewer for visual analysis of authors,institutions,keywords,etc.Results 910 Chinese literatures and 5 English literatures were included.The most published authors were Wang Changyin and Yin Chunping,and the institution was Handan Hospital of Traditional Chinese Medicine,Hebei Province.The cooperation between institutions was independent and regional.Research focus on:phlegm stasis interjunction,dyslipidemia,inflammatory factors,vascular endothelial function,nerve function defect,Banxia Baizhu Tianma decoction,coronary heart disease and so on;The treatment of CAS from"interjunction of phlegm and blood stasis"will continue to become a research hotspot in this field.Conclusion The clinical research of traditional Chinese medicine in the treatment of CAS should be closely combined with the observation of curative effect and the revelation of mechanism,and the law of traditional Chinese medicine in the treatment of CAS should be explored.In the future,the treatment of CAS should focus on the treatment of"phlegm and blood stasis",and the pathogenesis principle of"phlegm and blood stasis",the efficacy and mechanism of resolving phlegm and removing blood stasis in the treatment of CAS should be systematically and deeply explored.
5.Diagnostic value of PIV,APRI,and FIB-4 in intrahepatic cholestasis of pregnancy
China Modern Doctor 2025;63(26):33-36
Objective To investigate the diagnostic value of pan-immune-inflammation value(PIV),aspartate aminotransferase to platelet ratio index(APRI)and fibrosis-4 index(FIB-4)in intrahepatic cholestasis of pregnancy(ICP).Methods A total of 312 pregnant women who underwent prenatal care and childbirth at Anhui Women and Children's Medical Center from September 2022 to December 2024 were selected as subjects.Among them,156 patients diagnosed with ICP were included in ICP group,while 156 healthy pregnant women formed control group.The study compared differences in PIV,APRI,and FIB-4 levels between two groups.Receiver operating characteristic(ROC)curves were used to evaluate the predictive capabilities of PIV,APRI,and FIB-4 indicators for ICP occurrence,both individually and in combination.Results Inflammatory response is involved in the occurrence of ICP,and PIV,APRI,and FIB-4 have good diagnostic value for ICP.When PIV and APRI are combined,they have higher diagnostic value in ICP group showed significantly higher PIV,APRI,and FIB-4 levels compared to control group(P<0.05).The area under the curve(AUC)for diagnosing ICP using PIV,APRI,and FIB-4 were 0.636,0.751,and 0.627,respectively.When PIV combined with APRI,the diagnostic AUC reached 0.829 with sensitivity of 73.1%and specificity of 83.3%.Conclusion Inflammatory response is involved in the occurrence of ICP,and PIV,APRI and FIB-4 have good diagnostic value for ICP.Combination of PIV and APRI shows excellent diagnostic value.
6.Current situation analysis and quality evaluation of guidelines and consensus in ovarian stimulation for in vitro fertilization
Yuan GAO ; Zaiwei SONG ; Dan JIANG ; Rui YANG ; Yuwen HUANG ; Rong LI ; Rongsheng ZHAO
Chinese Journal of Reproduction and Contraception 2025;45(8):818-825
Objective:To systematically evaluate the current status and methodological quality of guideline and consensus in ovarian stimulation for in vitro fertilization (IVF), and to provide reference for the development of future guidelines and research. Methods:A systematic search was conducted in databases including PubMed, Embase, CNKI, Wanfang, Sinomed and relevant guideline websites from inceptions to October 2024. Data were extracted from the literature that met the inclusion criteria, and methodological quality was assessed using the Appraisal of Guidelines for Research and Evaluation Ⅱ (AGREE Ⅱ) tool. Descriptive analysis was performed with results presented in visual data charts.Results:A total of 23 studies were included, with 8 guidelines and 15 consensus. Totally 21 (91.3%) studies focused on the selection of ovarian stimulation protocols, with the majority concentrating on protocols for patients undergoing IVF treatment for the first cycle, and 12 (52.2%) studies focused on the selection of gonadotropin starting dosage. In terms of methodology, the average standardized scores in the 6 assessment domains of the AGREE Ⅱ tool were as follows: scope and purpose (85.1%), stakeholder involvement (66.6%), rigour of development (36.5%), clarity of presentation (70.1%), applicability (36.4%), and editorial independence (46.2%).Conclusion:Current recommendations in ovarian stimulation for IVF exhibit inconsistencies, and the methodological quality varies, which partially hinders the translation of evidence into clinical practice. Future research should further focus on the selection of ovarian stimulation protocols and gonadotropin starting dosage, promoting the update and refinement of guidelines and consensus to guide the precise treatment of ovarian stimulation.
7.Visual Analysis of Current Situation,Hotspot and Trend of Traditional Chinese Medicine in Treating Carotid Atherosclerosis Based on CiteSpace and VOSviewer
Yihuan CHEN ; Di ZHANG ; Yuwen XIA ; Junjie JIANG ; Cheng LYU ; Qingqiao SONG ; Yong TAN
World Science and Technology-Modernization of Traditional Chinese Medicine 2025;27(2):498-507
Objective To explore the current situation,hot spots and trends of clinical research on the treatment of carotid atherosclerosis(CAS)with traditional Chinese medicine.Methods Search CNKI,Wanfang,VIP,Web of Science core collection database related literature,using Python 3.9.6 cleaning data,using CiteSpace and VOSviewer for visual analysis of authors,institutions,keywords,etc.Results 910 Chinese literatures and 5 English literatures were included.The most published authors were Wang Changyin and Yin Chunping,and the institution was Handan Hospital of Traditional Chinese Medicine,Hebei Province.The cooperation between institutions was independent and regional.Research focus on:phlegm stasis interjunction,dyslipidemia,inflammatory factors,vascular endothelial function,nerve function defect,Banxia Baizhu Tianma decoction,coronary heart disease and so on;The treatment of CAS from"interjunction of phlegm and blood stasis"will continue to become a research hotspot in this field.Conclusion The clinical research of traditional Chinese medicine in the treatment of CAS should be closely combined with the observation of curative effect and the revelation of mechanism,and the law of traditional Chinese medicine in the treatment of CAS should be explored.In the future,the treatment of CAS should focus on the treatment of"phlegm and blood stasis",and the pathogenesis principle of"phlegm and blood stasis",the efficacy and mechanism of resolving phlegm and removing blood stasis in the treatment of CAS should be systematically and deeply explored.
8.Application of ArcherQA for independent dose verification of SRT plans for CyberKnife
Xuyao YU ; Yuwen WANG ; Yang DONG ; Daguang ZHANG ; Yongchun SONG ; Qiang REN ; Xi PEI ; Zhiyong YUAN ; Wei WANG ; Jianrong DAI
Chinese Journal of Radiation Oncology 2025;34(11):1139-1145
Objective:To evaluate the feasibility of using the domestic ArcherQA system for fast and simplified independent verification of CyberKnife (CK) stereotactic radiotherapy (SRT) plans.Methods:SRT plans of 57 patients treated with CK at Tianjin Medical University Cancer Institute and Hospital from August 2021 to August 2022 were retrospectively analyzed, including 15 intracranial, 30 pulmonary, and 12 abdominal tumors cases. Point-dose and planar-dose verifications were performed using an ionization chamber and radiochromic films embedded in a homogeneous phantom, and the results were compared with those calculated by the treatment planning system (TPS). The localization CT images and corresponding SRT plans were imported into the ArcherQA system for independent dose verification and analysis. The correlation between ArcherQA results and phantom measurements was analyzed, with comparisons of target mean dose differences and γ pass rates.Results:Phantom measurement results showed, the measured point-dose differences for intracranial, lung, and abdominal plans were -0.94% ± 3.22%, 1.92% ± 2.05%, and 2.12% ± 0.77%, respectively. The mean dose differences in target dose calculation between ArcherQA and TPS: intracranial in the gross tumor volume (GTV) regions were 0.34% ± 2.21%, lung tumor GTV were -2.47% ± 2.46%, and abdominal tumor GTV were 0.80% ± 2.61%, respectively. Among them, the abdominal GTV region showed the highest correlation between ArcherQA and measured results ( r=0.78). The average two-dimensional γ pass rates (2 mm/2%, threshold=10%) measured using phantom films were 95.92% ± 2.35% for intracranial, 95.70% ± 2.74% for lung, and 96.74% ± 3.41% for abdominal tumors plans, respectively. The three-dimensional ArcherQA results showed comparable γ pass rates (1 mm/2%, threshold=10%) for lung and abdominal GTV and PTV regions, with similar medians and data dispersion to film measurements. Conclusions:The ArcherQA system enables rapid and efficient independent dose verification of CK SRT plans without the need for additional hardware. The verification results show good correlation with phantom measurements, supporting its potential as an auxiliary quality assurance tool in clinical CK SRT implementation.
9.Analysis of the current status of clinical trial institutions for neuropsychiatric medical devices in China
Xin LI ; Yanfei YE ; Shijie SONG ; Yuwen WANG
China Modern Doctor 2024;62(33):43-46,150
Objective To explore the current status of medical device of clinical trial institutions specializing in psychiatry,neurology,and neurosurgery in China after the implementation of the registration system.Methods By searching the medical device clinical trial institution registration management information platform,statistical analysis was conducted on the number,category and grades,geographical distribution,number of principal investigators and aptitude,and cross-distribution of medical device clinical trial institutions specializing in psychiatry,neurology,and neurosurgery.Results Since the implementation of the registration system,up to August 6,2024,111 psychiatric,588 neurological,and 418 neurosurgical institutions that had registered distributed across 27,30,and 29 provincial-level administrative regions in China,respectively.Among these institutions,73.0%,66.5%and 76.6%were tertiary grade A hospitals,respectively.The number of registered principal investigators were 524,1635 and 1128 persons,respectively.The registered institutions were mainly distributed in relatively developed urban clusters in the Yangtze River Delta,Pearl River Delta,and Beijing-Tianjin-Hebei region.Conclusion Tertiary grade A hospitals dominate medical device clinical trial institutions specializing in psychiatry,neurology and neurosurgery in China.The implementation of the registration system has promoted the release of medical resources in the neuropsychiatric field.However,issues such as significant regional differences in the number of clinical trial institutions and the concentration of researcher resources exist.
10.Genetic analysis of transcription factors in dopaminergic neuronal development in Parkinson’s disease
Yuwen ZHAO ; Lixia QIN ; Hongxu PAN ; Tingwei SONG ; Yige WANG ; Xiaoxia ZHOU ; Yaqin XIANG ; Jinchen LI ; Zhenhua LIU ; Qiying SUN ; Jifeng GUO ; Xinxiang YAN ; Beisha TANG ; Qian XU
Chinese Medical Journal 2024;137(4):450-456
Background::Genetic variants of dopaminergic transcription factor-encoding genes are suggested to be Parkinson’s disease (PD) risk factors; however, no comprehensive analyses of these genes in patients with PD have been undertaken. Therefore, we aimed to genetically analyze 16 dopaminergic transcription factor genes in Chinese patients with PD.Methods::Whole-exome sequencing (WES) was performed using a Chinese cohort comprising 1917 unrelated patients with familial or sporadic early-onset PD and 1652 controls. Additionally, whole-genome sequencing (WGS) was performed using another Chinese cohort comprising 1962 unrelated patients with sporadic late-onset PD and 1279 controls.Results::We detected 308 rare and 208 rare protein-altering variants in the WES and WGS cohorts, respectively. Gene-based association analyses of rare variants suggested that MSX1 is enriched in sporadic late-onset PD. However, the significance did not pass the Bonferroni correction. Meanwhile, 72 and 1730 common variants were found in the WES and WGS cohorts, respectively. Unfortunately, single-variant logistic association analyses did not identify significant associations between common variants and PD. Conclusions::Variants of 16 typical dopaminergic transcription factors might not be major genetic risk factors for PD in Chinese patients. However, we highlight the complexity of PD and the need for extensive research elucidating its etiology.

Result Analysis
Print
Save
E-mail